Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
StemRIM Inc. ( (JP:4599) ) has issued an update.
StemRIM Inc. announced the completion of patient enrollment for an additional phase 2 clinical trial of Redasemtide, a treatment for dystrophic epidermolysis bullosa, which has been out-licensed to Shionogi & Co., Ltd. This trial aims to assess the efficacy of Redasemtide in closing refractory ulcers within 52 weeks, with the drug having been designated as an orphan drug by Japan’s Ministry of Health, Labour and Welfare. While the trial currently has no impact on the company’s financial results, it is expected to enhance corporate value in the medium to long term.
More about StemRIM Inc.
StemRIM Inc. is a biotech venture originating from Osaka University, focused on developing ‘Regeneration-Inducing Medicine™’. This innovative approach aims to achieve regenerative therapy effects through drug administration without using living cells or tissues, leveraging the body’s inherent ability to repair and regenerate damaged tissues. The company is working on advanced regenerative medicine products that mobilize mesenchymal stem cells to promote tissue repair, targeting various diseases such as epidermolysis bullosa, cerebral infarction, and cardiomyopathy.
Average Trading Volume: 190,998
Technical Sentiment Signal: Sell
Current Market Cap: Yen18.7B
Find detailed analytics on 4599 stock on TipRanks’ Stock Analysis page.